Article Sidebar

PDF (Tiếng Việt)
Published: 2025-07-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v192i7.3645
Issue
Vol. 192 No. 7 (2025)
Section
Các bài báo
How to Cite
Hưng, N. V., Hoài, N. T., Nhân, L. T., Thanh, M. P., Trang, T. Q., Anh, P. T. V., & Hà, N. T. T. (2025). 48. Nephroprotective effects of triterpenoid extracted from persimmon leaves (diospyros kaki l.F.) against Streptozotocin-induced diabetic nephropathy in type 2 diabetic mice. Journal of Medical Research, 192(7), 458-466. https://doi.org/10.52852/tcncyh.v192i7.3645

48. Nephroprotective effects of triterpenoid extracted from persimmon leaves (diospyros kaki l.F.) against Streptozotocin-induced diabetic nephropathy in type 2 diabetic mice

Nguyen Van Hung, Nguyen Thi Hoai, Le Trong Nhan, Mai Phuong Thanh, Tran Quynh Trang, Pham Thi Van Anh, Nguyen Thi Thu Ha

Main Article Content

Abstract

Diabetic nephropathy (DN) is a common complication in diabetic patients, characterized by a decline in kidney function. This study evaluated the nephroprotective effects of triterpenoid extract from persimmon leaves (Diospyros kaki L.f.) (Tri DKL) in type 2 diabetic mice with streptozotocin (STZ)-induced DN. Diabetic nephrotoxicity was induced in healthy Swiss mice through STZ injections (50 mg/kg). Mice were treated with Tri DKL at 250 mg/kg body weight (BW)/day or 750 mg/kg BW/day or dapagliflozin (1 mg/kg BW/day) for 28 days. Blood, urine, pancreas, and kidney samples were analyzed at the end of the study. The results showed that Tri DKL at 250 mg/kg BW/day and 750 mg/kg BW/day significantly increased urine output, glucose excretion, and creatinine clearance while slightly reducing urine protein and urine albumin and improving kidney histopathology. These findings suggest that Tri DKL exerts nephroprotective effects against STZ-induced DN.

Article Details

Keywords

Diabetic nephropathy, triterpenoid, persimmon leaves (Diospyros kaki L.f.), streptozotocin, mice

References

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. Jan 2010; 87(1): 4-14. https://doi.org/10.1016/j.diabres.2009.10.007.
2. Callaghan BC, Kerber KA, Lisabeth LL, et al. Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. JAMA Neurol. Sep 2014; 71(9): 1143-9. https://doi.org/10.1001/jamaneurol.2014.1279.
3. Agarwal R. Pathogenesis of Diabetic Nephropathy. Compendia. 2021; 2021(1): 2-7. https://doi.org/10.2337/db20211-2.
4. Han Y, Xu X, Tang C, et al. Reactive oxygen species promote tubular injury in diabetic nephropathy: The role of the mitochondrial ros-txnip-nlrp3 biological axis. Redox Biol. Jun 2018; 16:32-46. https://doi.org/10.1016/j.redox.2018.02.013.
5. Powers AC, D’Alessio D. Endocrine Pancreas and Pharmacotherapy of Diabetes Mellitus and Hypoglycemia. In: Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13e. McGraw-Hill Education; 2017.
6. Dsouza P, Holla R, Swamy G. Amelioration of Diabetic Nephropathy in Streptozotocin-Induced Diabetic Rats by Acacia catechu Leaves Extract. Journal of Health and Allied Sciences NU. 07/01 2019; 09: 116-120. https://doi.org/10.1055/s-0039-3402084.
7. Furman BL. Streptozotocin-Induced Diabetic Models in Mice and Rats. Curr Protoc Pharmacol. Sep 1 2015; 70: 5.47.1-5.47.20. https://doi.org/10.1002/0471141755.ph0547s70.
8. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton). Jun 2007; 12(3): 261-6. https://doi.org/10.1111/j.1440-1797.2007.00796.x.
9. Nguyen VH, Le TN, Le NTN, et al. Extraction, purification, and evaluation of bioactivities of total triterpenoids from Persimmon (Diospyros kaki L.f.) Leaves. Process Biochemistry. 2024/04/01/ 2024; 139: 70-80. https://doi.org/10.1016/j.procbio.2024.01.025.
10. Xie C, Xie Z, Xu X, Yang D. Persimmon (Diospyros kaki L.) leaves: A review on traditional uses, phytochemistry and pharmacological properties. Journal of Ethnopharmacology. 2015/04/02/ 2015; 163: 229-240. https://doi.org/10.1016/j.jep.2015.01.007.
11. Council NR. Guide for the Care and Use of Laboratory Animals: Eighth Edition. The National Academies Press; 2011: 246.
12. Kong L, Wang Y, Luo M, Tan Y, Cui W, Miao L. Prevention of Streptozotocin-Induced Diabetic Nephropathy by MG132: Possible Roles of Nrf2 and IκB. Oxid Med Cell Longev. 2017; 2017: 3671751. https://doi.org/10.1155/2017/3671751.
13. Widyatmaka M, Ismail A. The Effect of Antlion (Myrmeleon sp.) Extract Towards Histopathology Image of Pancreas in Diabetic Mice. Sains Medika. 01/04 2021; 11: 48. 10.30659/sainsmed.v11i2.7656.
14. Noshahr ZS, Salmani H, Khajavi Rad A, Sahebkar A. Animal Models of Diabetes-Associated Renal Injury. Journal of Diabetes Research. 2020; 2020(1): 9416419. https://doi.org/10.1155/2020/9416419.
15. Khandelwal P, Khanna S. Chapter 4 - Diabetic peripheral neuropathy: An insight into the pathophysiology, diagnosis, and therapeutics. In: Bagchi D, Das A, Roy S, eds. Wound Healing, Tissue Repair, and Regeneration in Diabetes. Academic Press; 2020: 49-77.
16. Guo L, Jiang B, Li D, Xiao X. Nephroprotective Effect of Adropinin Against Streptozotocin-Induced Diabetic Nephropathy in Rats: Inflammatory Mechanism and YAP/TAZ Factor. Drug Des Devel Ther. 2021; 15: 589-600. https://doi.org/10.2147/dddt.S294009.
17. Albarrán OG, Ampudia-Blasco FJ. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes]. Med Clin (Barc). Sep 2013; 141 Suppl 2:36-43. Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2. https://doi.org/10.1016/s0025-7753(13)70062-9.